Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions

References

• Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577. doi:10.1038/bcj.2017.53
   PubMed Web of Science ®Google Scholar
• Aldoss I, Forman SJ, Pullarkat V. Acute lymphoblastic leukemia in the older adult. J Oncol Pract. 2019;15(2):67–75. doi:10.1200/JOP.18.00271
   PubMed Web of Science ®Google Scholar
• Bourlon C, Lacayo-Leñero D, Inclán-Alarcón SI, Demichelis-Gómez R. Hematopoietic Stem cell transplantation for adult Philadelphia-negative acute lymphoblastic leukemia in the first complete remission in the era of minimal residual disease. Curr Oncol Rep. 2018;20(4):36. doi:10.1007/s11912-018-0679-9
   PubMed Web of Science ®Google Scholar
• Center of International Blood and Marrow Transplant Research Database. COVID-19 Updates from CIBMTR. Available from: https://www.cibmtr.org/Pages/index.aspx. Accessed December 16, 2022.
   Google Scholar
• Arslan S, Pullarkat V, Aldoss I. Indications for allogeneic HCT in adults with acute lymphoblastic leukemia in first complete remission. Curr Treat Options Oncol. 2021;22(7):63. doi:10.1007/s11864-021-00860-1
   PubMed Web of Science ®Google Scholar
• Greil C, Engelhardt M, Ihorst G. Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia. Bone Marrow Transplant. 2021;56(4):841–852. doi:10.1038/s41409-020-01101-z
   PubMed Web of Science ®Google Scholar
• Spyridonidis A. How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. Blood. 2020;135(19):1639–1649. doi:10.1182/blood.2019003566
   PubMed Web of Science ®Google Scholar
• Michael A, Pulsipher BLF. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 children’s oncology group/pediatric blood and marrow transplant consortium trial. Blood. 2014;123(13):2017–2025. doi:10.1182/blood-2013-10-534297
   PubMed Web of Science ®Google Scholar
• Pulsipher MA. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplant. 2015;50(9):1173–1179. PMID: 25961775; PMCID: PMC4573663. doi:10.1038/bmt.2015.103
   PubMed Web of Science ®Google Scholar
• Michael A, Pulsipher CSF. Striking predictive power for relapse and decreased survival associated with detectable minimal residual disease by IGH VDJ deep sequencing of bone marrow pre- and post-allogeneic transplant in children with B-lineage all: a subanalysis of the COG ASCT043. Blood. 2013;919. doi:10.1182/blood.V122.21.919.919
   Google Scholar
• Wethmar K, Matern S, Eßeling E. Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia. Bone Marrow Transplant. 2020;55(7):1410–1420. doi:10.1038/s41409-020-0801-0
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Acute lymphoblastic leukemia (version4.2021); 2021.
   Google Scholar
• Bader P, Kreyenberg H, von Stackelberg A, et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015;33:1275–1284. doi:10.1200/JCO.2014.58.4631
   PubMed Web of Science ®Google Scholar
• Balduzzi A, Di Maio L, Silvestri D, et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? Br J Haematol. 2014;164:396–408. doi:10.1111/bjh.12639
   PubMed Web of Science ®Google Scholar
• Merli P, Ifversen M, Truong TH. Minimal residual disease prior to and after haematopoietic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia: what level of negativity is relevant? Front Pediatr. 2021;9:777108. doi:10.3389/fped.2021.777108
   PubMed Web of Science ®Google Scholar
• Terwey TH, Hemmati PG, Nagy M. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2014;20(10):1522–1529. doi:10.1016/j.bbmt.2014.05.026
   PubMed Web of Science ®Google Scholar
• Phelan R, Arora M, Chen M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides; 2020.
   Google Scholar
• Riviello-Goya S, Acosta-Medina AA, Inclan-Alarcon SI, Garcia-Miranda S, Bourlon C. Isolated extramedullary relapse in acute lymphoblastic leukemia: what can we do before and after transplant? Oncology. 2020;34(2):39–43.
   PubMed Web of Science ®Google Scholar
• Yuda S, Fuji S, Onishi A. Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(6):1152–1157. doi:10.1016/j.bbmt.2019.01.011
   PubMed Web of Science ®Google Scholar
• Shem-Tov N, Saraceni F, Danylesko I. Isolated extramedullary relapse of acute leukemia after allogeneic stem cell transplantation: different kinetics and better prognosis than systemic relapse. Biol Blood Marrow Transplant. 2017;23(7):1087–1094. doi:10.1016/j.bbmt.2017.03.023
   PubMed Web of Science ®Google Scholar
• Hamdi A, Mawad R, Bassett R. Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(11):1767–1771. doi:10.1016/j.bbmt.2014.07.005
   PubMed Web of Science ®Google Scholar
• Larson RA. Managing CNS disease in adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(1):3–13. doi:10.1080/10428194.2017.1326597
   PubMed Web of Science ®Google Scholar
• O’Brien S, Schiller G, Lister J. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31(6):676–683. doi:10.1200/JCO.2012.46.2309
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102(7):2379–2386. doi:10.1182/blood-2003-03-0925
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Stein AS. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66. doi:10.1016/S1470-2045(14)71170-2
   PubMed Web of Science ®Google Scholar
• Stein AS, Kantarjian H, Gökbuget N. Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(8):1498–1504. doi:10.1016/j.bbmt.2019.04.010
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gökbuget N. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847. doi:10.1056/NEJMoa1609783
   PubMed Web of Science ®Google Scholar
• Martinelli G, Boissel N, Chevallier P. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive b-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35(16):1795–1802. doi:10.1200/JCO.2016.69.3531
   PubMed Web of Science ®Google Scholar
• Mahmoud R, Banerjee P, Milton DR. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022;139(12):1908–1919. doi:10.1182/blood.2021013290
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Banerjee PP, Ganesh C, et al. Blinatumomab is well tolerated maintenance therapy following allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood. 2019;134(Supplement_1):1298. doi:10.1182/blood-2019-125931
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bonifacio M. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–1531. doi:10.1182/blood-2017-08-798322
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J. Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403–411. doi:10.1016/S1470-2045(11)70386-2
   PubMed Web of Science ®Google Scholar
• Kantarjian HM. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753. doi:10.1056/NEJMoa1509277
   PubMed Web of Science ®Google Scholar
• Metheny L. Post-transplant inotuzumab ozogamicin for acute lymphoblastic leukemia. Blood. 2021;138(Supplement 1):2899. doi:10.1182/blood-2021-153041
   Google Scholar
• Sasaki K. Sequential combination of low-intensity chemotherapy (mini-hyper-CVD) plus inotuzumab ozogamicin with or without blinatumomab in patients with relapsed/refractory Philadelphia chromosome negative acute lymphoblastic leukemia (ALL): a phase 2 trial. Blood. 2018;132(Supplement 1):553.
   PubMedGoogle Scholar
• Jabbour E. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4(2):230–234. doi:10.1001/jamaoncol.2017.2380
   PubMed Web of Science ®Google Scholar
• Sasaki K. Sequential combination of Inotuzumab Ozogamicin (InO) with low-intensity chemotherapy (mini-hyper-CVD) with or without blinatumomab is highly effective in patients (pts) with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in First Relapse. Blood. 2019;134(Supplement_1):3806.
   Google Scholar
• Sasaki K. Long-term follow-up of the combination of low-intensity chemotherapy plus inotuzumab ozogamicin with or without blinatumomab in patients with relapsed-refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 trial. Blood. 2020;136(Supplement 1):40–42.
   Google Scholar
• Ej. W. T cell exhaustion. Nat Immunol. 2011;12(6):492–499. PMID: 21739672. doi:10.1038/ni.2035
   PubMed Web of Science ®Google Scholar
• Deol A. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev. 2010;36(7):528. doi:10.1016/j.ctrv.2010.03.004
   PubMed Web of Science ®Google Scholar
• Bader P. Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT. Anticancer Res. 1996;16(4A):1759–1763.
   PubMed Web of Science ®Google Scholar
• Ramírez M, Díaz MA, García-Sánchez F. Chimerism after allogeneic hematopoietic cell transplantation in childhood acute lymphoblastic leukemia. Bone Marrow Transplant. 1996;18(6):1161–1165.
   PubMed Web of Science ®Google Scholar
• McSweeney PA. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390–3400. doi:10.1182/blood.V97.11.3390
   PubMed Web of Science ®Google Scholar
• Georges GE, Storb R, Thompson JD. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood. 2000;95(10):3262–3269. doi:10.1182/blood.V95.10.3262
   PubMed Web of Science ®Google Scholar
• Spitze Tr. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist. 2000;5:215–223. doi:10.1634/theoncologist.5-3-215
   PubMedGoogle Scholar
• Bader P. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol. 2004;22(9):1696–1705. doi:10.1200/JCO.2004.05.198
   PubMed Web of Science ®Google Scholar
• Alida Dominietto GP, Piaggio G, Pozzi S. Treatment of Minimal Residual Disease (MRD) with Donor Lymphocyte Infusions (DLI) in acute leukemia patients undergoing an allogeneic Hemopoietic Stem Cell Transplants (HSCT). Blood. 2005;106(11):2012. doi:10.1182/blood.V106.11.2012.2012
   Web of Science ®Google Scholar
• Yan C-H, Liu Q-F, Wu D-P. Prophylactic Donor Lymphocyte Infusion (DLI) followed by minimal residual disease and graft-versus-host disease–guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute. Biol Blood Marrow Transplant. 2017;23(8):1311–1319. doi:10.1016/j.bbmt.2017.04.028
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM. European group for blood and marrow transplantation working party chronic leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041–2050. doi:10.1182/blood.V86.5.2041.bloodjournal8652041
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767–776. doi:10.1182/blood-2003-02-0342
   PubMed Web of Science ®Google Scholar
• Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2008;41(5):483–493. doi:10.1038/sj.bmt.1705898
   PubMed Web of Science ®Google Scholar
• Choi SJ, Lee J-H, Lee J-H. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. Bone Marrow Transplant. 2005;36(2):163–169. doi:10.1038/sj.bmt.1705024
   PubMed Web of Science ®Google Scholar
• Cardoso AA, Schultze JL, Boussiotis VA. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996;88(1):41–48. doi:10.1182/blood.V88.1.41.41
   PubMed Web of Science ®Google Scholar
• Galandrini R, Albi N, Zarcone D, Grossi CE, Velardi A. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity. Eur J Immunol. 1992;22:2047–2053. doi:10.1002/eji.1830220814
   PubMed Web of Science ®Google Scholar
• Han P, Story C, McDonald T, Mrozik K, Snell L. Immune escape mechanisms of childhood ALL and a potential countering role for DC-like leukemia cells. Cytotherapy. 2002;4:165–175. doi:10.1080/146532402317381875
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E. Effectiveness of donor natural killer alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100. doi:10.1126/science.1068440
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Bunin N. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2006;107(4):1325–1331. doi:10.1182/blood-2005-08-3373
   PubMed Web of Science ®Google Scholar
• Durer C, Durer S, Shafqat M, et al. Concomitant use of blinatumomab and donor lymphocyte infusion for post-transplant relapsed CD19 positive acute lymphoblastic leukemia: systematic review. Blood. 2018;132(Supplement 1):5742. doi:10.1182/blood-2018-99-109998
   Google Scholar
• Papayannidis C, Sartor C, Dominietto A, et al. Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant. Hematol Oncol. 2021;39(4):580–583. PMID: 33963566. doi:10.1002/hon.2886
   PubMed Web of Science ®Google Scholar
• Lubbert M. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant. 2010;45:627–632. doi:10.1038/bmt.2009.222
   PubMed Web of Science ®Google Scholar
• Schroeder T, Czibere A, Platzbecker U. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27:1229–1235. doi:10.1038/leu.2013.7
   PubMed Web of Science ®Google Scholar
• Levine JE. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol. 2002;20(2):405–412. doi:10.1200/JCO.2002.20.2.405
   PubMed Web of Science ®Google Scholar
• Guillaume T, Gaugler B, Chevallier P. Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity. Bone Marrow Transplant. 2012;47(8):1112–1117. doi:10.1038/bmt.2011.231
   PubMed Web of Science ®Google Scholar
• Chang XZ, Zang X, Xia C-Q. New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2015;51:324–332. doi:10.1038/bmt.2015.288
   PubMed Web of Science ®Google Scholar
• Porter DL, Collins RH, Hardy C. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood. 2000;95(4):1214–1221.
   PubMed Web of Science ®Google Scholar
• Innes AJ. Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplant. 2013;48(10):1324–1328. doi:10.1038/bmt.2013.69
   PubMed Web of Science ®Google Scholar
• Lewalle P. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant. 2003;31(1):39–44. doi:10.1038/sj.bmt.1703779
   PubMed Web of Science ®Google Scholar
• Bar M, Sandmaier BM, Inamoto Y. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant. 2013;19(6):949–957. doi:10.1016/j.bbmt.2013.03.001
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong ASM, Savani BN. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood. 2007;110(6):1924–1932. doi:10.1182/blood-2007-03-076844
   PubMed Web of Science ®Google Scholar
• Nagler A, Labopin M, Dholaria B. second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the acute leukaemia working party of the European society for blood and marrow transplantation. Br J Haematol. 2019;186(5):767–776. doi:10.1111/bjh.15973
   PubMed Web of Science ®Google Scholar
• Eapen M. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004;34(8):721–727. doi:10.1038/sj.bmt.1704645
   PubMed Web of Science ®Google Scholar
• Kishi K. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplantation. 1997;19(5):721–727. doi:10.1038/sj.bmt.1700680
   PubMed Web of Science ®Google Scholar
• Poon L. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013;48:666–670.
   PubMed Web of Science ®Google Scholar
• Michallet M. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the société française de greffe de moelle. Br J Haematol. 2000;108(2):400–407.
   PubMed Web of Science ®Google Scholar
• Al-Shaibani E. Comparison of outcomes after second allogeneic hematopoietic cell transplantation versus donor lymphocyte infusion in allogeneic hematopoietic cell transplant patients. Clin Lymphoma Myeloma Leuk. 2021;11:1.
   Google Scholar
• Yalniz FF. Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia. Transplant Cell Ther. 2021;27(8):689–695. doi:10.1016/j.jtct.2021.05.007
   PubMedGoogle Scholar
• Shimoni A. Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the acute leukemia working party of EBMT. Blood Cancer J. 2019;9(12):88. doi:10.1038/s41408-019-0251-3
   PubMedGoogle Scholar
• Maude SF. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Eng J Med. 2014;371(16):1507–1517.
   PubMed Web of Science ®Google Scholar
• Shah BG. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.
   PubMed Web of Science ®Google Scholar
• Maude SL. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Eng J Med. 2018;378(5):439–448.
   PubMed Web of Science ®Google Scholar
• Rives S. S112: tisagenlecleucel in pediatric and young adult patients (Pts) with relapsed /refractory (R/R) B –cell Acute Lymphoblastic Leukemia (B-ALL): final analysis from the ELIANA study. Hema Sphere. 2022;6:13–14.
   Google Scholar
• Pasquini MC. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414–5424. doi:10.1182/bloodadvances.2020003092
   PubMed Web of Science ®Google Scholar
• Anagnostou T. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematol. 2020;7(11):e816–e826. PMID:33091355. doi:10.1016/S2352-3026(20)30277-5
   PubMed Web of Science ®Google Scholar
• Myers RM. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022;40(9):932–944. PMID: 34767461; PMCID: PMC8937010. doi:10.1200/JCO.21.01405
   PubMed Web of Science ®Google Scholar
• Pillai V. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3(22):3539–3549.
   PubMed Web of Science ®Google Scholar
• Jiang H. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial. Am J Hematol. 2019;94(10):1113–1122.
   PubMed Web of Science ®Google Scholar
• Gardner RA. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–3333.
   PubMed Web of Science ®Google Scholar
• Myers RM. Humanized CD19-targeted Chimeric Antigen Receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol. 2021;39(27):3044–3055.
   PubMed Web of Science ®Google Scholar
• Shah NN. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021;39(15):1650–1659.
   PubMed Web of Science ®Google Scholar
• Frey NV. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol. 2020;38(5):415–422.
   PubMed Web of Science ®Google Scholar
• Hay KA. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652–1663.
   PubMed Web of Science ®Google Scholar
• Park JH. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–459.
   PubMed Web of Science ®Google Scholar
• Wang N. Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. Blood. 2020;135(1):17–27.
   PubMed Web of Science ®Google Scholar
• Youle RJ. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47–59.
   PubMed Web of Science ®Google Scholar
• Alford SE, Chambers TC. BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 2015;75(7):1366–1375.
   PubMed Web of Science ®Google Scholar
• Frismantas V. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017;129(11):e26–e37.
   PubMed Web of Science ®Google Scholar
• Pullarkat VA. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440–1453. PMID: 33593877. doi:10.1158/2159-8290.CD-20-1465
   PubMed Web of Science ®Google Scholar
• Park SH. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis. Cytometry B Clin Cytom. 2020;98(4):336–347.
   PubMed Web of Science ®Google Scholar
• Feucht J. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget. 2016;7(47):76902–76919.
   PubMed Web of Science ®Google Scholar
• Wunderlich M, Manning N, Sexton C. PD-1 inhibition enhances blinatumomab response in a UCB/PDX model of relapsed pediatric B-cell acute lymphoblastic leukemia. Front Oncol. 2021;11:642466. doi:10.3389/fonc.2021.642466
   PubMed Web of Science ®Google Scholar
• Webster J, Luskin MR, Prince GT. Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patient swith relapsed/refractory (R/R) CD19 positive B-cell Acute Lymphoblastic Leukemia (ALL): preliminary results of a phase I study. Blood. 2018;29:557. doi:10.1182/blood-2018-99-111845
   Google Scholar
• Ijaz A, Khan AY, Malik SU. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant. 2019;25(1):94–99. PMID: 30195074; PMCID: PMC6310648. doi:10.1016/j.bbmt.2018.08.028
   PubMed Web of Science ®Google Scholar
• Blaeschke F, Stenger D, Apfelbeck A. Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins. Blood Cancer J. 2021;11(6):108. doi:10.1038/s41408-021-00499-z
   PubMed Web of Science ®Google Scholar
• Li S, Siriwon N, Zhang X. Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors. Clin Cancer Res. 2017;23(22):6982–6992. doi:10.1158/1078-0432.CCR-17-0867
   PubMed Web of Science ®Google Scholar
• Rafiq S, Yeku OO, Jackson HJ. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847–856. doi:10.1038/nbt.4195
   PubMed Web of Science ®Google Scholar
• Rupp LJ, Schumann K, Roybal KT. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737. doi:10.1038/s41598-017-00462-8
   PubMed Web of Science ®Google Scholar
• Krivtsov AV, Evans K, Gadrey JY. A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell. 2019;36(6):660–673.e611. doi:10.1016/j.ccell.2019.11.001
   PubMed Web of Science ®Google Scholar
• Borkin D, He S, Miao H. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015;27(4):589–602. doi:10.1016/j.ccell.2015.02.016
   PubMed Web of Science ®Google Scholar
• Naik J, Themeli M, de Jong-Korlaar R. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica. 2019;104(3):e100–e103. doi:10.3324/haematol.2018.192757
   PubMed Web of Science ®Google Scholar
• Tembhare PR. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. J Immunother Cancer. 2020;8(1):1.
   Web of Science ®Google Scholar
• Bras AE, Beishuizen A, Langerak AW. CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy. Br J Haematol. 2018;180(2):292–296. doi:10.1111/bjh.14310
   PubMed Web of Science ®Google Scholar
• Bride KL, Vincent TL, Im S-Y. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131(9):995–999. doi:10.1182/blood-2017-07-794214
   PubMed Web of Science ®Google Scholar
• Vogiatzi F, Winterberg D, Lenk L. Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. Blood. 2019;134(8):713–716. doi:10.1182/blood.2019000904
   PubMed Web of Science ®Google Scholar
• Ofran Y, Ringelstein-Harlev S, Slouzkey I. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia. Leukemia. 2020;34(1):293–295. doi:10.1038/s41375-019-0548-z
   PubMed Web of Science ®Google Scholar
• Diorio C, Murray R, Naniong M, et al. Teachey; Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood. 2022;140(6):619–629. doi:10.1182/blood.2022015825
   PubMed Web of Science ®Google Scholar